Qynapse Inc. is a medical technology company that provides an AI-powered neuroimaging software platform for central nervous system (CNS) disorders. The company announced a rebrand which will include a new logo and a complete redesign of its website, aiming to better reflect its focus and commitment to excellence.
Qynapse has recently reached a number of important milestones, tackling new global markets such as Asia Pacific while maintaining a strong focus in Europe and North America, reinforcing the company’s stance as a neuroscience industry leader. The company aims to improve its offering, to create more accurate, more reliable screening and monitoring of CNS disease in both clinical routine settings and clinical trial applications. Quynapse leveraged its world-renowned team of scientific and clinical partners to develop one of the largest datasets of proprietary algorithms. This dataset provides over 200 measures of neurodegeneration and neuroinflammation, allowing specialists to rapidly and accurately analyze and interpret brain scans.
“Before the inception of Qynapse in 2015, we envisioned a future where neuroimaging AI was widely accepted and adopted as a critical solution for both clinical routine and clinical trials. Today, major steps have been achieved towards that vision. We are excited to launch our new brand identity that better reflects the organization Qynapse has become, committed to bringing game-changing technology to serve a brighter and more accurate future of diagnosis and treatment for patients with brain disorders,” said Qynapse CEO, Olivier Courrèges.
“As an industry, our thinking has evolved. AI is now a critical partner with humans to drive impactful change across the healthcare ecosystem. For healthcare providers, payers, pharma and, above all, patients, we aim to bring ground-breaking peace of mind by providing results they can trust, and our new brand identity makes this motivation shine through. It also reflects our long-term vision, to combine imaging data together with other biomarkers and patient modalities to positively impact clinical trial outcomes and facilitate decision making across the CNS care continuum,” concluded Matt Ullum, Chief Commercial Officer at Qynapse.
Visit the new Qynapse website: www.qynapse.com
